Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC

NCT00001450 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

NIH

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms

Interventions

DRUG: paclitaxel
DRUG: cisplatin

Sponsor

National Cancer Institute (NCI)